Blue Shield of Calif. is bypassing traditional pharmacy benefit managers to bring a Humira-referenced biosimilar, Idacio, to ...

TEVA reports better-than-expected third-quarter results, beating both earnings and sales estimates. However, the stock declines 7%.

Dealmaking this year has been largely muted, but M&A trends are pointing to the areas where pharma is placing the most ...

Arthritis is a common acute or chronic condition affecting the joints and surrounding tissues. It’s estimated that roughly 18 ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

Medically reviewed by Mary Choy, PharmDJoint pain can be caused by a number of biological, psychological, and social factors.

The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to ...

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

Asset Management One Co. Ltd. increased its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 0.6% during the 3rd quarter, according to the company in its most recent disclosure with the ...

Reorganizing its generics business strategy to target 60% instead of 80% of drugs coming off patent and reallocating resources to complex generics will help Teva offset base business erosion and ...